IP Library Granted Patent US 9,777,311
Granted Patent B2
US 9,777,311 · App. 14/053,252 · Granted Oct 3, 2017

Synthetic

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,777,311
App. No.
14/053,252
Granted
Oct 3, 2017
Kind
B2
Abstract

A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type Oplophorus luciferase and includes at least one amino acid substitution at a position corresponding to an amino acid in a wild-type Oplophorus luciferase of SEQ ID NO:1. The modified luciferase polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the wild-type Oplophorus luciferase.

Claims (8)

1. A method comprising:

(a) expressing a luminescent polypeptide in a cell, wherein the luminescent polypeptide comprises a modified luciferase with at least 70% sequence identity with SEQ NO: 1 and having one or more amino acid substitutions at positions 4, 11, 43, 44, 54, 72, 75, 90, 115, 124, 138, and 166 relative to SEQ ID NO: 1, wherein the modified luciferase has at least one of enhanced luminescence, enhanced signal stability; and enhanced protein stability relative to a luciferase of SEQ ID NO; 1;

(b) exposing said cell to a substrate for said modified luciferase; and

(c) detecting luminescence.

2. The method of claim 1 , wherein the substrate is coelenterazine or a coelenterazine derivative.

3. The method of claim 2 , wherein the coelenterazine is selected from coelenterazine, coelenterazine n, coelenterazine h, coelenterazine c, coelenterazine cp, coelenterazine e, coelenterazine f, coelenterazine fcp, coelenterazine i, coelenterazine icp or coelenterazine 2-methyl.

4. The method of claim 1 , wherein the luminescent polypeptide is expressed as a fusion with a polypeptide of interest.

5. The method of claim 1 , further comprising a step prior to step (a) of introducing into the cell a vector comprising a nucleic acid sequence encoding the luminescent polypeptide.

Assignments (2)
SECURITY INTEREST Recorded Apr 3, 2019
From: PROMEGA CORPORATION; PROMEGA BIOSCIENCES, LLC; TERSO SOLUTIONS, INC.; ORION SEVEN, LLC; PROMEGA AVIATION LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 048790/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2014
From: ENCELL, LANCE P.; HALL, MARY; OTTO, PAUL; VIDUGIRIS, GEDIMINAS; WOOD, KEITH V.; WOOD, MONIKA G.; ZIMMERMAN, KRISTOPHER
To: PROMEGA CORPORATION
Reel/Frame 031880/0623 →